We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-3.41%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$800M
AUM Growth
-$94.7M
Cap. Flow
-$16.1M
Cap. Flow %
-2.01%
Top 10 Hldgs %
66.9%
Holding
36
New
3
Increased
1
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$44.4M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$43.2M
3
CBAY
Cymabay Therapeutics
CBAY
+$20M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.8M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$51.1M
2
NTRA icon
Natera
NTRA
+$33.6M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$25.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.2M
5
TVRD
Tvardi Therapeutics
TVRD
+$4.57M

Sector Composition

Rank Sector Weight
1 Healthcare 98.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
26
Tango Therapeutics
TNGX
$4.31B
$7.59M 0.95%
1,921,790
– –
SYRS
27
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.67M 0.71%
2,124,694
– –
NAUT icon
28
Nautilus Biotechnolgy
NAUT
$114M
$5.54M 0.69%
2,000,000
– –
CCCC icon
29
C4 Therapeutics
CCCC
$480M
$5.16M 0.64%
1,642,210
– –
THRD
30
DELISTED
Third Harmonic Bio
THRD
$2.64M 0.33%
640,631
-511,026
-44% -$2.17M
IVVD icon
31
Invivyd
IVVD
$216M
$2.33M 0.29%
1,937,207
– –
SYRE icon
32
Spyre Therapeutics
SYRE
$9.18B
$1.55M 0.19%
213,908
– –
APTX
33
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.11M 0.14%
8,891,758
– –
NAMSW icon
34
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$184K 0.02%
100,000
– –
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$5.07B
– –
-701,402
Closed -$11.2M
PTGX icon
36
Protagonist Therapeutics
PTGX
$9.84B
– –
-2,364,410
Closed -$25.8M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q1 2023 Portfolio in Review

As of Q1 2023, Bain Capital Life Sciences Investors held 36 positions worth $800M, down 11% from $895M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Bain Capital Life Sciences Investors's Q1 2023 filing shows 3 new, 1 increased, 4 reduced and 2 closed positions. Its largest new stake was Disc Medicine: 1,990,914 shares worth $42.2M. The largest sale was SpringWorks Therapeutics, an estimated $51.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

  • Bain Capital Life Sciences Investors's largest Q1 2023 buy was Disc Medicine: 1,990,914 shares worth $42.2M.
  • Bain Capital Life Sciences Investors added most to CTI BioPharma Corp. (DE) Common Stock in Q1 2023, an estimated $4.8M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2023 reduction was SpringWorks Therapeutics, cutting an estimated $51.1M.
  • Bain Capital Life Sciences Investors fully exited Protagonist Therapeutics in Q1 2023, selling an estimated $25.8M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 67% of its $800M portfolio in Q1 2023.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q1 2023.
  • Bain Capital Life Sciences Investors's portfolio value fell 11% quarter-over-quarter to $800M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2023, filed 15 May 2023.